Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q2 2024 · 10-Q
Revenue$16.09M$16.09M+11.0% vs Q2 2023 Net Income-$12.60M-$12.60MN/M vs Q2 2023 EPS Diluted-$0.51-$0.51N/M vs Q2 2023 Gross Profit$11,073,000+8.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,697,000N/M Free Cash Flowderived-$10,996,000N/M Margins · derivedGross margin68.8%−1.6 pt vs Q2 2023
Operating margin-71.9%−0.4 pt vs Q2 2023
Net margin-78.3%−3.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end